Bremelanotide

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Retrieved on: 
Friday, February 9, 2024
Palatine, Conference call, Conference, Bremelanotide, Webcast, PTN

CRANBURY, N.J., Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2024, at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
    US Toll Free Dial-In Number:

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Retrieved on: 
Wednesday, January 3, 2024
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Patient, Orange Book, HSDD, Multimedia, Woman, Acquisition, Medication, Education, Bremelanotide, PTN, Female, Urology

Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of Vyleesi® from Palatin Technologies, Inc. (NYSE: PTN), which includes 5 Orange Book listed patents with protection up to 2041.

Key Points: 
  • Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of Vyleesi® from Palatin Technologies, Inc. (NYSE: PTN), which includes 5 Orange Book listed patents with protection up to 2041.
  • Palatin and Cosette will ensure continued patient and healthcare professional access to Vyleesi® throughout the transition period.
  • Cosette offers patients the ability to connect with a physician through a telemedicine option.
  • Patients and providers can learn more about HSDD and Vyleesi®, including Important Safety Information, at www.vyleesi.com .

Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023

Retrieved on: 
Thursday, November 9, 2023
Palatine, Conference call, Bremelanotide, Webcast, Conference, NYSE, PTN

CRANBURY, N.J., Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2023, at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
    US Toll Free Dial-In Number:

Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment

Retrieved on: 
Monday, October 16, 2023
NYSE, Inflammation, Safety, United European Gastroenterology, Bremelanotide, Colitis, DSS, Inflammatory bowel disease, UEG, Melanocortin, Conference, Patient, Poster, Pharmaceutical industry, Rat, Palatine

The poster is currently available on the UEG 2023 Conference website.

Key Points: 
  • The poster is currently available on the UEG 2023 Conference website.
  • "This important mechanism of action data supports our active business development efforts for PL8177, including continued enrollment of patients in a Phase 2 ulcerative colitis study."
  • The poster presents data from a series of oral PL8177 dose-ranging studies in the DSS colon inflammation model and includes histological, genomic, and proteomic data.
  • PL8177 treatment showed clear evidence of resolving pathological inflammation by repolarizing colon macrophages from a pro-inflammatory to a pro-inflammation resolving state.

Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023

Retrieved on: 
Friday, September 22, 2023
Bremelanotide, PTN, Palatine, Conference call, Conference, NYSE, Webcast

CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 28, 2023, at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
    US Toll Free Dial-In Number:

Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Thursday, September 7, 2023
Bremelanotide, PTN, Webcast, Conference, NYSE, Fine chemical, Broadcasting, Palatine

CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.

Key Points: 
  • CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.
  • The Company presentation will be held on Wednesday, September 13, 2023 at 10:00 a.m.
  • A live webcast of the presentation will be available on the Investors section of Palatin's website at http://www.palatin.com .
  • A replay of the webcast will be available for 30 days following the presentation.

Palatin's Vyleesi® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Retrieved on: 
Tuesday, August 8, 2023
PTN, Hypoactive sexual desire disorder, Fosun Pharma, Marketing, FTZ, MFDS, Woman, Prescription, Sale, Korean Ministry of Culture, Arousal, South Korea, Patient, HSDD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, NMPA, Safety, Medical tourism, Pharmaceutical industry, Bremelanotide, Palatine, Fosun International

Palatin also announced that their South Korean licensee, Kwangdong Pharmaceuticals, completed enrollment in its Phase 3 clinical trial evaluating the efficacy and safety of Vyleesi in premenopausal women with HSDD.

Key Points: 
  • Palatin also announced that their South Korean licensee, Kwangdong Pharmaceuticals, completed enrollment in its Phase 3 clinical trial evaluating the efficacy and safety of Vyleesi in premenopausal women with HSDD.
  • Data from this trial is anticipated by year end with a potential regulatory submission in the first half of 2024.
  • "This first commercial sale, coupled with the completed enrollment in the Phase 3 clinical trial in South Korea, strengthens our position in the Asian marketplace.
  • In exchange, Palatin received an upfront payment of $500,000 and is due a $3.0 million milestone based on the first commercial sale in Korea.

Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®

Retrieved on: 
Monday, August 7, 2023
PTN, Telehealth, Partnership, Education, Woman, Patient, FDA, HSDD, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Female, Pharmaceutical industry, Bremelanotide

CRANBURY, N.J., Aug. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered a strategic partnership with UpScriptHealth, a leading direct-to-consumer telemedicine company providing telemedicine services to pharmaceutical and medical technology companies. Under terms of the agreement, UpScriptHealth will make Vyleesi available to the hundreds of thousands of patients in its proprietary Women's Telehealth Platform. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Key Points: 
  • Under terms of the agreement, UpScriptHealth will make Vyleesi available to the hundreds of thousands of patients in its proprietary Women's Telehealth Platform.
  • Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
  • "We are excited to partner with UpScriptHealth, a pioneer in telehealth," stated Carl Spana, Ph.D., President and Chief Executive Officer of Palatin.
  • "This partnership fortifies our existing telehealth programs and provides a platform to create greater awareness of HSDD and access to Vyleesi through UpScriptHealth's patient base of hundreds of thousands of women."

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Retrieved on: 
Wednesday, July 26, 2023
Therapy, Roche, MGD, Research, Inflammation, VAV1, Patient, Bremelanotide, Drug discovery, Knowledge, Biogen, Manning, Johnson & Johnson, Autoimmunity, Pharmaceutical industry, Momenta

BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.

Key Points: 
  • BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.
  • Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases.
  • Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we’re delighted to have him on our team,” said Markus Warmuth, M.D., CEO of Monte Rosa.
  • Dr. Manning has contributed more than 120 scientific publications and patents in the fields of autoimmune diseases, novel therapeutics, and drug discovery.

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

Retrieved on: 
Thursday, May 11, 2023
Bremelanotide, PTN, Palatine, Conference call, Conference, NYSE, Webcast

CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets.

Key Points: 
  • CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets.
  • Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, 2023, at 11:00 a.m.
  • The conference call will include a review of the company's operating results and an update on programs under development.
  • Schedule for the Operating Results Press Release, Conference Call / Audio Webcast
    US Toll Free Dial-In Number: